Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397760 | 0.81 | HTR2A (0.63) | HTR2ATAAR1 | |
| SCHEMBL27133821 | 0.81 | TAAR1 (0.57) | HTR2ATAAR1 | |
| SCHEMBL397761 | 0.81 | HTR2A (0.63) | HTR2ATAAR1 | |
| SCHEMBL2560760 | 0.81 | HTR2A (0.54) | HTR2ATAAR1 | |
| SCHEMBL5267699 | 0.81 | HTR2A (0.54) | HTR2A | |
| SCHEMBL2564900 | 0.80 | HTR2A (0.53) | HTR2A | |
| SCHEMBL2560674 | 0.80 | HTR2A (0.53) | HTR2ATAAR1 | |
| SCHEMBL14655631 | 0.79 | HTR2A (0.51) | HTR2ATAAR1 | |
| SCHEMBL14655633 | 0.79 | HTR2A (0.51) | HTR2ATAAR1 | |
| SCHEMBL17767069 | 0.78 | HTR2A (0.63) | HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4304576-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Ensysce Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192197-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Ensysce Biosciences Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | 3I, LP | 2022-09-15 | — | — | US | disclosed |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2020-08-13 | — | — | US | disclosed |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2016-08-18 | — | — | US | disclosed |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2560486-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012122412-A2 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2011133347-A1 | COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | HTR2A 375/4885TAAR1 238/4885 |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | HTR2A 375/4885TAAR1 238/4885 |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | DNPEP, PEPD, CEL | HTR2A 3854/4885TAAR1 2755/4885 |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | HTR2A 823/4885TAAR1 1084/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | HTR2A 2491/4885TAAR1 543/4885 |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | HTR2A 375/4885TAAR1 238/4885 |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | HTR2A 375/4885TAAR1 238/4885 |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | HTR2A 375/4885TAAR1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.